NGS 기반 RNA 시퀀싱 시장 : 규모, 점유율 및 동향 분석 보고서 - 제품 및 서비스별, 워크플로우별, 용도별, 최종 용도별, 지역별 부문 예측(2025-2030년)

NGS-based RNA-sequencing Market Growth & Trends:

The global NGS-based RNA-sequencing market size is expected to reach USD 10.05 billion by 2030 and is anticipated to grow at a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to rising demand for precision medicine, advancements in sequencing technologies, and increasing applications in diagnostics, drug discovery, and disease research. Expanding bioinformatics capabilities and declining sequencing costs further support widespread market adoption.

The COVID-19 pandemic has accelerated the adoption of NGS-based RNA-sequencing owing to its critical role in understanding viral mutations, host response, and pathogen transcriptomics. The urgent need for advanced genomic tools in vaccine and therapeutic development highlighted the value of RNA-sequencing, driving rapid integration into research and public health efforts. This shift has reinforced its importance in infectious disease monitoring and preparedness.

In addition, advancements in high-throughput sequencing technologies have significantly enhanced the speed, accuracy, and scalability of RNA-sequencing. These innovations enable more comprehensive transcriptome profiling, reduce turnaround times, and lower costs, making NGS-based RNA sequencing more accessible for both research and clinical applications.

However, high initial costs associated with sequencing platforms and infrastructure, and ethical concerns surrounding genomic data usage are expected to hamper market growth. These challenges may limit adoption, particularly in resource-constrained settings and regions with stringent data privacy regulations.

NGS-based RNA-sequencing Market Report Highlights:

• Based on product and service, the consumables segment dominated with the largest revenue share of 58.12% in 2024, due to continuous advancements in reagent chemistry and the growing demand for quality, efficient sequencing kits. However, services are expected to grow at the fastest CAGR over the forecast period.
• Based on workflow, the sequencing segment held the largest market share in 2024, driven by increased adoption of advanced platforms offering faster turnaround and cost-effective processing. On the other hand, the data analysis segment is anticipated to witness the fastest CAGR of 18.49% over the forecast period.
• Based on application, the drug discovery & development segment holds the largest revenue share for application in 2024. This is attributed to the growing use of RNA-sequencing in identifying novel targets and accelerating therapeutic development. However, the clinical diagnostics segment is projected to grow at the highest CAGR over the forecast period.
• Based on end use, the pharmaceutical & biotechnology companies segment held the largest share in 2024. The growth is due to increased adoption of RNA-sequencing for biomarker discovery, clinical research, and personalized drug development. On the other hand, the hospitals & clinics segment is expected to register the fastest growth rate during the projected period.
• North America dominated the NGS-based RNA-sequencing market owing to factors such as advanced healthcare infrastructure, strong research funding, and high adoption of precision medicine and genomic technologies. Asia Pacific is expected to grow at the fastest CAGR during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Workflow
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. NGS-based RNA-sequencing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for precision and personalized medicine
    • 3.2.1.2. Growing applications in biomarker discovery and drug development
    • 3.2.1.3. Integration of AI and bioinformatics for data interpretation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High initial costs associated with sequencing platforms and infrastructure
    • 3.2.2.2. Ethical issues surrounding genomic data usage
• 3.3. NGS-based RNA-sequencing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. NGS-based RNA-sequencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global NGS-based RNA-sequencing Market Product & Service Movement Analysis
• 4.3. Global NGS-based RNA-sequencing Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Consumables
  • 4.4.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Extraction & Purification Kits
    • 4.4.2.1. Extraction & purification kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Library Preparation Kits
    • 4.4.3.1. Library preparation kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Sequencing Reagents & Flow Cells
    • 4.4.4.1. Sequencing reagents & flow cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. RNA-sequencing
    • 4.6.2.1. RNA-sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Bioinformatics & Data Analysis
    • 4.6.3.1. Bioinformatics & data analysis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. NGS-based RNA-sequencing Market: Workflow Estimates & Trend Analysis

• 5.1. Workflow Segment Dashboard
• 5.2. Global NGS-based RNA-sequencing Market Workflow Movement Analysis
• 5.3. Global NGS-based RNA-sequencing Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 5.4. Pre-sequencing
  • 5.4.1. Pre-sequencing market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Sequencing
  • 5.5.1. Sequencing market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Data Analysis
  • 5.6.1. Data analysis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. NGS-based RNA-sequencing Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global NGS-based RNA-sequencing Market Application Movement Analysis
• 6.3. Global NGS-based RNA-sequencing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Drug Discovery & Development
  • 6.4.1. Drug discovery & development market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Oncology
    • 6.4.2.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Infectious Diseases
    • 6.4.3.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Others
    • 6.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Diagnostics
  • 6.5.1. Clinical diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. NGS-based RNA-sequencing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global NGS-based RNA-sequencing Market End Use Movement Analysis
• 7.3. Global NGS-based RNA-sequencing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Hospitals & Clinics
  • 7.5.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. NGS-based RNA-sequencing Market: Regional Estimates & Trend Analysis by Product & Service, Workflow, Application, and End Use

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.9. Denmark
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Regulatory framework
    • 8.5.9.3. Competitive scenario
    • 8.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Regulatory framework
    • 8.8.5.3. Competitive scenario
    • 8.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Illumina, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. QIAGEN N.V.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Merck KGaA
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Pacific Biosciences of California, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Oxford Nanopore Technologies Ltd.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. BGI Group
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Agilent Technologies, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Roche Holding AG
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Revvity, Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives